中國同輻(01763.HK)與ITM訂立技術許可協議 引進先進核素生產技術
格隆匯11月18日丨中國同輻(01763.HK)宣佈,於2019年11月18日,公司的一家控股附屬公司成都高通與ITM訂立一份技術許可協議。根據技術許可協議,ITM將授予成都高通在中國使用ITM的生產及加工技術生產及銷售面向中國市場的不加載體的(n.c.a.)177Lu(EndolucinBeta®)和68Ge/68Ga發生器的權利。根據技術許可協議,ITM應向成都高通提供相關的支持服務。成都高通和ITM還將在中國設立銷售合資企業,具體條款待雙方進一步談判確定。
董事會認為,通過與ITM合作在中國進行n.c.a.177Lu和68Ge/68Ga發生器的生產,引進先進的核素生產技術。公司將實現重要新型醫用核素的國產化、規模化生產。通過該協議,公司將因加入全球ITMOEM網絡而成為國際上重要的n.c.a.177Lu和68Ge/68Ga發生器供應基地。在提升我國重要、新型核素生產能力的同時為我國放射性藥物研發生產和核醫學產業的發展和診療水平的提升做出貢獻。
ITM是根據德國法律成立的股份公司及一傢俬有生物技術及放射性藥物集團公司,致力於創新性診斷和治療用放射性核素和放射性藥物的開發、生產和全球供應。許可方擁有用於診斷和治療神經內分泌癌、前列腺癌、骨轉移癌以及其他癌症的醫用放射性核素和放射性藥物的特定專利、專有技術和商標,或持有前述專利、專有技術和商標的排他權利。
成都高通是根據中國法律組建的國有控股企業,是公司的控股附屬公司。成都高通以放射性同位素產品的開發、生產和銷售為主業,兼營進出口貿易、貨物運輸。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.